| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Awards, appointments
|
Carter, Stephen
|
|
|
6 |
10 |
p. 959
|
artikel
|
| 2 |
Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables*
|
Binder, C.
|
|
|
6 |
10 |
p. 1005-1010
|
artikel
|
| 3 |
Book review
|
Joss, R.
|
|
|
6 |
10 |
p. 1050
|
artikel
|
| 4 |
Cell cycle regulation and the function of cancer genes
|
Zucca, E.
|
|
|
6 |
10 |
p. 975-978
|
artikel
|
| 5 |
Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma
|
Gabarre, J.
|
|
|
6 |
10 |
p. 1025-1032
|
artikel
|
| 6 |
Commitment demanded for lung cancer research
|
Me Vie, G.
|
|
|
6 |
10 |
p. 979
|
artikel
|
| 7 |
Copyright
|
|
|
|
6 |
10 |
p. ii
|
artikel
|
| 8 |
Corrigendum
|
Mitsdomi, T.
|
|
|
6 |
10 |
p. 1051
|
artikel
|
| 9 |
Dutch medical association re(de)fines guidelines euthanasia 1984
|
Spanjer, Marjanke
|
|
|
6 |
10 |
p. 958
|
artikel
|
| 10 |
Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients
|
Rosti, G.
|
|
|
6 |
10 |
p. 1045-1047
|
artikel
|
| 11 |
European CME in oncology progresses; recognition of medical oncology less so
|
Wagener, Theo
|
|
|
6 |
10 |
p. 958-959
|
artikel
|
| 12 |
Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC)
|
Larsen, H.
|
|
|
6 |
10 |
p. 993-997
|
artikel
|
| 13 |
Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases
|
Rochlitz, C.F.
|
|
|
6 |
10 |
p. 981-986
|
artikel
|
| 14 |
FDA: Close to approval of taxotere
|
|
|
|
6 |
10 |
p. 958
|
artikel
|
| 15 |
First-line systemic therapy for metastatic breast cancer and management of pleural effusion
|
Perrone, F.
|
|
|
6 |
10 |
p. 1033-1043
|
artikel
|
| 16 |
Index of athours Volume 6 (1995)
|
|
|
|
6 |
10 |
p. 1069-1075
|
artikel
|
| 17 |
Index of Subjects Volume 6 (1995)
|
|
|
|
6 |
10 |
p. 1053-1068
|
artikel
|
| 18 |
Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas
|
Poorter, R.L.
|
|
|
6 |
10 |
p. 1048-1049
|
artikel
|
| 19 |
In this issue
|
|
|
|
6 |
10 |
p. 955
|
artikel
|
| 20 |
Matrix metalloproteinase inhibition: A review of anti-tumour activity
|
Brown, P.D.
|
|
|
6 |
10 |
p. 967-974
|
artikel
|
| 21 |
Perhaps not everyone knows that
|
|
|
|
6 |
10 |
p. 959-960
|
artikel
|
| 22 |
Pharmacia-Upjohn merger: Gain of No. 2 position, loss of 4,000 jobs
|
|
|
|
6 |
10 |
p. 957
|
artikel
|
| 23 |
p53, myc, APC, hMSH2, ras, etc. in colorectal cancer — a never ending story!
|
Fey, Martin F.
|
|
|
6 |
10 |
p. 961-962
|
artikel
|
| 24 |
Randomised study using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cell cancer
|
Sagaster, P.
|
|
|
6 |
10 |
p. 999-1003
|
artikel
|
| 25 |
Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects
|
Lopez, M.
|
|
|
6 |
10 |
p. 1011-1017
|
artikel
|
| 26 |
Stem cells in the clinic: Early reports show promise
|
Deckman, Steven
|
|
|
6 |
10 |
p. 956-957
|
artikel
|
| 27 |
Table of Contents
|
|
|
|
6 |
10 |
p. i-ii
|
artikel
|
| 28 |
The Djerba statement: Just another declaration, or a new beginning?
|
Cavalli, F.
|
|
|
6 |
10 |
p. 963-964
|
artikel
|
| 29 |
The fight against cancer in countries with limited resources
|
Costa, A.
|
|
|
6 |
10 |
p. 965-966
|
artikel
|
| 30 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial
|
Gebbia, V.
|
|
|
6 |
10 |
p. 987-991
|
artikel
|
| 31 |
Vincristine, doxorabicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma — a multicenter phase II study
|
Bergmann, L.
|
|
|
6 |
10 |
p. 1019-1024
|
artikel
|
Tijdschrift beschrijving